Moderna prices $2.6 billion convertible senior notes offering

Moderna has priced an upsized $2.6 billion offering of convertible senior notes, increasing the amount from a previously announced $2.0 billion. The pharmaceutical company intends to use the proceeds for general corporate purposes, including investments in its oncology business and debt repayment. This move aims to strengthen the company's financial position and support strategic growth initiatives.